JP4718637B2 - ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用 - Google Patents

ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用 Download PDF

Info

Publication number
JP4718637B2
JP4718637B2 JP2009527908A JP2009527908A JP4718637B2 JP 4718637 B2 JP4718637 B2 JP 4718637B2 JP 2009527908 A JP2009527908 A JP 2009527908A JP 2009527908 A JP2009527908 A JP 2009527908A JP 4718637 B2 JP4718637 B2 JP 4718637B2
Authority
JP
Japan
Prior art keywords
amino
pyrimidin
methyl
trans
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009527908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010503653A (ja
Inventor
チェング ヘングミアオ
ブフムラルカー ディリップ
ルプレクト ドレス クラウス
エリザベス ホフマン ジャッキー
キャサリン ジョンソン マリー
スティーヴン カニア ロバート
シ クイ レ フオング
デイヴィッド ナムブ ミッチェル
アラン ペアリッシュ メイソン
ブルーノ プレウェ マイケル
トゥアン トラン クハンフ
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2010503653A publication Critical patent/JP2010503653A/ja
Application granted granted Critical
Publication of JP4718637B2 publication Critical patent/JP4718637B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
JP2009527908A 2006-09-15 2007-09-03 ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用 Active JP4718637B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US60/845,065 2006-09-15
US94785207P 2007-07-03 2007-07-03
US60/947,852 2007-07-03
US95262807P 2007-07-30 2007-07-30
US60/952,628 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (2)

Publication Number Publication Date
JP2010503653A JP2010503653A (ja) 2010-02-04
JP4718637B2 true JP4718637B2 (ja) 2011-07-06

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527908A Active JP4718637B2 (ja) 2006-09-15 2007-09-03 ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用

Country Status (41)

Country Link
US (3) US7696213B2 (enExample)
EP (1) EP2074122B9 (enExample)
JP (1) JP4718637B2 (enExample)
KR (1) KR101099926B1 (enExample)
CN (1) CN101573358B (enExample)
AP (1) AP2710A (enExample)
AR (1) AR062785A1 (enExample)
AT (1) ATE514695T1 (enExample)
AU (1) AU2007297212B8 (enExample)
BR (1) BRPI0716749B8 (enExample)
CA (1) CA2663401C (enExample)
CL (1) CL2007002682A1 (enExample)
CR (1) CR10662A (enExample)
CU (1) CU23783B7 (enExample)
CY (1) CY1111911T1 (enExample)
DK (1) DK2074122T5 (enExample)
DO (1) DOP2009000039A (enExample)
EA (1) EA016388B1 (enExample)
ES (1) ES2366489T3 (enExample)
GE (1) GEP20115306B (enExample)
GT (1) GT200700077A (enExample)
HN (1) HN2007000267A (enExample)
HR (1) HRP20110621T2 (enExample)
IL (1) IL197243A (enExample)
MA (1) MA30709B1 (enExample)
ME (1) MEP8009A (enExample)
MX (1) MX2009002927A (enExample)
MY (1) MY146420A (enExample)
NI (1) NI200900032A (enExample)
NO (1) NO342357B1 (enExample)
NZ (1) NZ575167A (enExample)
PE (1) PE20080670A1 (enExample)
PL (1) PL2074122T3 (enExample)
PT (1) PT2074122E (enExample)
RS (2) RS20090104A (enExample)
SI (1) SI2074122T1 (enExample)
TN (1) TN2009000085A1 (enExample)
TW (1) TWI334353B (enExample)
UY (1) UY30588A1 (enExample)
WO (1) WO2008032162A1 (enExample)
ZA (1) ZA200901477B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115306B (enExample) 2006-09-15 2011-10-10 Pfizer Prod Inc
UA100979C2 (ru) * 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
NZ579945A (en) * 2007-04-11 2012-05-25 Exelixis Inc Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
RU2508110C2 (ru) * 2008-07-11 2014-02-27 Новартис Аг КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
TW201020238A (en) * 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282571B2 (en) 2008-08-20 2014-12-11 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR073524A1 (es) * 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
CA2820078C (en) 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
MX2014002471A (es) 2011-08-31 2014-03-27 Novartis Ag Combinaciones sinergicas de los inhibidores de p13k y mek.
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
WO2016015598A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
JP6784668B2 (ja) 2014-10-10 2020-11-11 ファイザー・インク 相乗的オーリスタチン組合せ
HUE047477T2 (hu) 2015-06-04 2020-04-28 Pfizer Palbociclib szilárd dózisformái
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
ES3002745T3 (en) 2016-07-06 2025-03-07 Univ Michigan Regents Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
JP6563623B1 (ja) 2016-08-15 2019-08-21 ファイザー・インク ピリドピリミジノンｃｄｋ２／４／６阻害剤
CA3045041A1 (en) * 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
IL312844A (en) * 2021-11-18 2024-07-01 Onconova Therapeutics Inc Methods and compositions for treating cancer
JP2024544632A (ja) 2021-12-03 2024-12-03 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２及びｐｅｒｋキナーゼ阻害剤としての複素環式化合物
UY40772A (es) 2023-06-08 2024-12-31 Nimbus Wadjet Inc Inhibidores de wrn
WO2025137599A1 (en) * 2023-12-21 2025-06-26 Nimbus Wadjet, Inc. Wrn inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
RU2191188C2 (ru) 1994-11-14 2002-10-20 Варнер-Ламберт Компани Производные 6-арилпиридо[2,3-d]-пиримидины и -нафтиридины, фармацевтическая композиция, обладающая ингибирующим действием клеточной пролиферации, вызываемой протеиновой тирозинкиназой, и способ ингибирования клеточной пролиферации
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
CN1433417A (zh) 2000-01-27 2003-07-30 沃尼尔·朗伯公司 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
YU66502A (sh) 2000-03-06 2005-09-19 Warner-Lambert Company 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
JP4166991B2 (ja) 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
MXPA04010267A (es) 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
JP2007504283A (ja) 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
JP4053073B2 (ja) 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的ｃｄｋ４阻害剤のイセチオン酸塩
BRPI0412876A (pt) 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CN1918158B (zh) 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
JP2007523151A (ja) 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
BRPI0510560A (pt) * 2004-05-04 2007-11-20 Warner Lambert Co pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
MXPA06014021A (es) 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
CA2585091C (en) 2004-11-03 2016-07-19 University Of Kansas Novobiocin analogues as anticancer agents
EP1828186A1 (en) 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
JP2010500994A (ja) 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
GEP20115306B (enExample) * 2006-09-15 2011-10-10 Pfizer Prod Inc
JP5577104B2 (ja) * 2007-03-14 2014-08-20 エクセリクシス パテント カンパニー エルエルシー ヘッジホッグ経路の阻害剤
NZ579945A (en) * 2007-04-11 2012-05-25 Exelixis Inc Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
AR073524A1 (es) * 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor
WO2011130628A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
US7696213B2 (en) 2010-04-13
RS20090104A (sr) 2010-06-30
CU20090040A7 (es) 2011-07-11
NO20091141L (no) 2009-03-31
CU23783B7 (es) 2012-02-15
WO2008032162A8 (en) 2009-03-26
US20100137279A1 (en) 2010-06-03
BRPI0716749B8 (pt) 2021-05-25
WO2008032162A1 (en) 2008-03-20
IL197243A0 (en) 2009-12-24
ES2366489T9 (es) 2013-12-27
US8633204B2 (en) 2014-01-21
SI2074122T1 (sl) 2011-10-28
IL197243A (en) 2013-07-31
BRPI0716749B1 (pt) 2020-10-06
CY1111911T1 (el) 2015-11-04
HN2007000267A (es) 2011-02-25
CA2663401C (en) 2011-07-12
JP2010503653A (ja) 2010-02-04
AP2710A (en) 2013-07-30
CN101573358B (zh) 2012-05-30
AR062785A1 (es) 2008-12-03
CL2007002682A1 (es) 2008-04-04
MA30709B1 (fr) 2009-09-01
HRP20110621T1 (hr) 2011-09-30
KR20090040389A (ko) 2009-04-23
DK2074122T3 (da) 2011-08-15
EP2074122B9 (en) 2013-09-11
US20080090801A1 (en) 2008-04-17
PT2074122E (pt) 2011-08-24
MX2009002927A (es) 2009-03-31
DOP2009000039A (es) 2015-12-15
CA2663401A1 (en) 2008-03-20
TWI334353B (en) 2010-12-11
PE20080670A1 (es) 2008-06-14
ZA200901477B (en) 2010-07-28
BRPI0716749A2 (pt) 2014-02-18
US8273755B2 (en) 2012-09-25
EA200970207A1 (ru) 2009-08-28
PL2074122T3 (pl) 2011-10-31
EP2074122B1 (en) 2011-06-29
MY146420A (en) 2012-08-15
AU2007297212A1 (en) 2008-03-20
ATE514695T1 (de) 2011-07-15
GEP20115306B (enExample) 2011-10-10
MEP8009A (en) 2011-12-20
EP2074122A1 (en) 2009-07-01
EA016388B1 (ru) 2012-04-30
ES2366489T3 (es) 2011-10-20
US20120309775A1 (en) 2012-12-06
UY30588A1 (es) 2008-05-02
GT200700077A (es) 2009-08-03
CR10662A (es) 2009-04-17
AU2007297212B8 (en) 2011-04-28
TW200820972A (en) 2008-05-16
AP2009004790A0 (en) 2009-04-30
DK2074122T5 (da) 2014-03-17
HK1138589A1 (en) 2010-08-27
RS51927B (sr) 2012-02-29
TN2009000085A1 (fr) 2010-08-19
NZ575167A (en) 2010-10-29
AU2007297212B2 (en) 2011-04-14
CN101573358A (zh) 2009-11-04
KR101099926B1 (ko) 2011-12-28
NO342357B1 (no) 2018-05-14
HRP20110621T2 (hr) 2013-12-06
NI200900032A (es) 2010-05-14

Similar Documents

Publication Publication Date Title
JP4718637B2 (ja) ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用
AU2024201172C1 (en) Pyrrolotriazine compounds as tam inhibitors
JP4792126B2 (ja) ピラゾール化合物およびＲａｆ阻害剤としてのその使用
US12398146B2 (en) Heterobicyclic amides as inhibitors of CD38
JP2009530261A (ja) ピラゾール化合物
JP2008531542A (ja) 抗癌剤として有用な二環式複素芳香族誘導体
JP2011530580A (ja) 強力なｈｓｐ−９０阻害剤としての２−アミノピリミジン化合物
US20250333419A1 (en) Bicyclic compounds as inhibitors of wrn
HK1138589B (en) Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100901

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100901

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20101005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110322

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110331

R150 Certificate of patent or registration of utility model

Ref document number: 4718637

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250